Renal hemodynamic effects of lovastatin in a renal ablation model

Urology

Volumn 48, Issue 6, 1996, Pages 862-867

  Hafez, Khaled S ^a   Inman, Sharon R ^a   Stowe, Nicholas T ^a   Novick, Andrew C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; MEVINOLIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY FUNCTION TEST; KIDNEY SURGERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ANIMALS; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; KIDNEY; LOVASTATIN; MALE; NEPHRECTOMY; RATS; RATS, WISTAR;

EID: 0030452968     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00314-7     Document Type: Article

References (38)

1. Novick AC, Gephardt G, Guz B, Steinmuller D, and Tubbs RR: Long-term follow-up after partial removal of a solitary kidney. N Engl J Med 325: 1058-1062, 1991.
2. Schimamura T, and Morrison AB: A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 79: 95-106, 1975.
3. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, and Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 245: F85-F93, 1981.
4. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 249: F324-F337, 1985.
5. Klahr S, Heifets M, and Purkerson ML: The Progressive Nature Of Renal Disease. New York, Churchill Livingstone, 1986, pp 45-55.
6. Bank N, and Aynedjian HS: Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 43: 1306-1312, 1993.
7. Remuzzi G, and Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384-394, 1990.
8. Diamond JR, and Karnovsky MJ: Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 33: 917-924, 1988.
9. Kasiske BL, O'Donnell MP, Garvis WJ, and Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62: 367-374, 1988.
10. Lee SK, Jin SY, Han DC, Hwang SD, and Lee HB: Effects of delayed treatment with enalapril and lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 8: 1338-1343, 1993.
11. Sokal RR, and Rohlf FJ: Biometry, 2nd ed. New York, Freeman, 1981.
12. D'Amico G, and Gentile MG: Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients. Kidney Int 39: S65-S69, 1991.
13. O'Donnell MP, Kasiske BL, Kim Y, Schmitz PG, and Keane WF: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 22: 83-89, 1993.
14. Kasiske BL, O'Donnell MP, Clearly MP, and Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33: 667-672, 1988.
15. Harris KPG, Purkerson ML, Yates J, and Klahr S: Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 15: 16, 1990.
16. O'Donnell MP, Kasiske BL, Katz SA, Schmitz PG, and Keane WF: Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 20: 651-658, 1992.
17. Brouhard BH, Takamori H, Satoh S, Inman SR, Cressman M, Irwin K, Berkley V, and Stowe NT: The combination of lovastatin and enalapril in a model of progressive renal disease. Pediatr Nephrol 8: 436-440, 1994.
18. Modi KS, Schreiner GF, Purkerson ML, and Klahr S: Effects of probucol in renal function and structure in rats with subtotal kidney ablation. J Lab Clin Med 120: 310-317, 1992.
19. Washio M, Nanishi F, Onoyama K, Okuda S, and Fujishima M: Effects of anti-hyperlipidemic agent of dietary protein restriction on progressive renal deterioration in adriamycin-induced nephropathy in rats. Int Nephrol Urol 25: 295-303, 1993.
20. Griffin K A, Picken M, and Bidani AK: Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 4: 2023-2031, 1994.
21. Iaina A, Benyamin G, Levtov O, Getter R, Serban I, Wollman Y, Rubinstein A, Cabili S, Peer G, and Blum M: Effect of chronic cholesterol loading in the development of acute ischemic renal failure in rats. Renal Failure 16: 117-123, 1994.
22. Bank N: Renal hemodynamic consequences of hyperlipidemia. Miner Electrolyte Metab 19: 165-172, 1993.
23. Keane WF, Kasiske BL, and O'Donnell MP: The role of lipids in progressive glomerular disease. Adv Exp Med Biol 223: 81-87, 1987.
24. Kasiske BL, O'Donnell MP, Cowardin W, and Keane WF: Lipids and the kidney. Hypertension 15: 443-450, 1990.
25. Keane WF, Kasiske BL, and O'Donnell MP: Hyperlipidemia and the progression of renal disease. Am J Clin Nutr 47: 157-160, 1988.
26. Keane WF, Kasiske BL, O'Donnell MP, and Kim Y: Hypertension, hyperlipidemia, and renal damage. Am J Kidney Dis 21: 43-50, 1993.
27. Stowe NT, Inman SR, Tapolyai M, Brouhard BH, Hodge EE, and Novick AC: Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol 156: 249-252, 1996.
28. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, and Keane WF: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91: 83-87, 1993.
29. Aviram M, Danker G, Cogan U, Hochgraf E, and Brook G: Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 42: 229, 1992.
30. Grone EF, Abboud HE, Hohne M, Walli AK, Grone H-J, Stuker D, Robenek H, Wieland, and Seidel D: Actions of lipoproteins in cultured human mesangial cells: modulation by mitogenic vasoconstrictors. Am J Physiol 263 (Renal Fluid Electrolyte Physiol 32) : F686-F696, 1992.
31. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, and Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487, 1995.
32. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, and Ganz P: The effect of cholesterol-lowering and anti-oxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488-493, 1995.
33. Foster MH, Sant GR, Donohoe JF, and Harrington JT: Prolonged survival with a remnant kidney. Am J Kidney Dis 17: 261-265, 1991.
34. Lhotta K, Eberle H, Koning P, and Dittrich P: Renal function after tumor enucleation in a solitary kidney. Am J Kidney Dis 17: 266-270, 1991.
35. Solomon LR, Mallick NP, and Lawler W: Progressive renal failure in a remnant kidney. Br Med J 291: 1610-1611, 1985.
36. Stahl RAK, Low I, and Schoeppe W: Progressive renal failure in a patient after one and two-thirds nephrectomy. Klin Wochenschr 66: 508-510, 1988.
37. Rutsky EA, Dubovsky EV, and Kirk K: Long-term follow-up of a human subject with a remnant kidney. Am J Kidney Dis 18: 509-513, 1991.
38. Novick AC, and Schreiber MJ: Effect of angiotensin-converting enzyme inhibition on nephropathy in patients with a remnant kidney. Urology 46: 785-789, 1995.